GUTS Overview

Fractyl Health, Inc. is a metabolic therapeutics company. The Company is focused on developing new approaches to the treatment of metabolic diseases, including obesity and type 2 diabetes (T2D). The Company’s lead product candidate, Revita, is designed to remodel the duodenal lining via hydrothermal ablation (i.e. duodenal mucosal resurfacing) to reverse damage to intestinal nutrient sensing and signaling mechanisms caused by chronic high-fat and high-sugar diets that are a root cause of metabolic disease. The Revita clinical program is focused on patients living with obesity who want to maintain their weight loss after GLP-1 drug discontinuation. The Company’s Rejuva platform focuses on developing adeno-associated virus (AAV)-based, locally delivered gene therapies for the treatment of obesity and T2D. The Rejuva platform leverages advanced delivery systems and proprietary screening methods to identify and develop metabolically active gene therapy candidates targeting the pancreas.

Wall Street analysts forecast GUTS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GUTS is5.00 USD with a low forecast of 2.00 USD and a high forecast of 8.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Fractyl Health Inc revenue for the last quarter amounts to 0.00 USD, decreased -100.00

Fractyl Health Inc. EPS for the last quarter amounts to -0.71 USD, increased 47.92

Fractyl Health Inc (GUTS) has 107 emplpoyees as of March 31 2026.

Today GUTS has the market capitalization of 67.74M USD.